HUTCHMED (China) vs Legend Biotech
HCM and LEGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCM and LEGN compare
Legend Biotech grew revenue faster over the last twelve months (59.5% versus −13.0% for HUTCHMED (China)).
HUTCHMED (China) scores higher on the StockData Score (5 against 3 for Legend Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCM | LEGN |
|---|---|---|
| Size and price | ||
| Share price | $14.40 | $16.11 |
| Change, 1 year | −4.5% | −46.8% |
| Change, 5 years | −59.1% | −70.2% |
| Beta (5Y) | 0.75 | 0.80 |
| Employees | 109 | 2,900 |
| StockData Score | ||
| Total score | 5 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −13.0% | 59.5% (better) |
| Revenue growth, 5Y average | 19.2% | 68.8% (better) |
| Net income growth (TTM) | 1111% | – |
| EPS growth (TTM) | 1200% | – |
| Profitability | ||
| Gross margin | 38.7% | 57.2% (better) |
| Operating margin | −7.1% | −4.3% (better) |
| Net margin | 83.3% | – |
| FCF margin | −14.4% | −9.6% (better) |
| Return on equity | 36.7% | – |
| Financial health | ||
| Debt / equity | 0.09 | – |
| Interest coverage | −13.7× | −2.5× (better) |
| Current ratio | 5.64 (better) | 3.04 |
| Piotroski F-score | 4 | – |
| Ownership | ||
| Held by institutions | 0.51% | 28.4% |
| Held by insiders | 0.44% | 0.50% |
| Insider net buying, 12 months | – | −$384K |
| Superinvestors holding | – | 1 |
Go deeper
- HCM stock overview
- HCM income statement
- HCM valuation and score
- LEGN stock overview
- LEGN income statement
- LEGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.